Un Kwon is a co-founder & the CEO of Dahlia Biosciences. Dahlia is developing cell-based RNA detection tools using CRISPR-Cas9 technology. Previously, Un was the Chief Strategy Officer at Caribou Biosciences, a CRISPR-Cas9 gene editing technology platform company spun out from the laboratory of Dr. Jennifer Doudna. Prior to Caribou, Un was the VP of Corporate Development at Fluidigm, a life science tools company focused on single-cell-analysis, and a life science tools/diagnostics investment research analyst at Pacific Growth Equities. Un has a M.Sc. in Molecular and Cellular Biology from University of Toronto, B.Sc. in Biochemistry from Queen's University, and is a Chartered Financial Analyst.
Lunch Seminar with Astellas: Launching the Astellas and MBC BioLabs Golden Ticket Competition
September 11, 2019 12:30 to 1:30 PM MBC BioLabs - 953 Indiana Street, San Francisco Lunch Served
Attend this Seminar to learn about innovation at Astellas, including the Company's therapeutic and platform technology focus areas, science-led investment strategy and collaborative partnering approach – launching the call for Golden Ticket Competition entries to help accelerate innovative life science start-ups into real businesses that can bring value to patients.
Dr. Matsumoto is the president of AVM, the wholly-owned venture capital organization within Astellas Pharma Inc. (Astellas). He established Astellas Innovation Management LLC, headquartered in Cambridge, Massachusetts, to explore emerging innovation in life sciences and served as its president for two years until March 2018. He also previously served as divisional senior vice president, Innovation & Incubation Research Labs, Drug Discovery Research, Astellas Pharma Inc. in Japan.
NAVAN Technologies, Inc., (NAVAN) is a pre-clinical stage biotechnology company developing and commercializing its proprietary NanoStraw platform technology, which establishes a direct, physical connection into cells to overcome a huge challenge faced by researchers globally: delivering material into hard-to-transfect-cells in an efficient yet gentle and non-perturbative manner. Cargo delivery via NanoStraws will drastically reduce the working steps, costs and technical difficulties involved in cell therapy manufacturing. By overcoming viability and manufacturing challenges plaguing traditional viral-based development, NAVAN is actively pursuing innovative therapies in a broad range of indications via strategic collaboration with numerous biopharma companies.